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Abstract: BACKGROUND AIMS Intestinal epithelial homeostasis depends on a tightly regulated bal-
ance between intestinal epithelial cell (IEC) death and proliferation. Disruption of factors that promote
IEC death result in intestinal inflammation, whereas loss of anti-apoptotic proteins, such as BCL2 or its
family member BCL2L1, has no effect on intestinal homeostasis in mice. We investigated the functions
of the anti-apoptotic protein MCL1, another member of the BCL2 family, in intestinal homeostasis in
mice. METHODS We generated mice with IEC-specific disruption of Mcl1 (Mcl1IEC mice) or tamoxifen-
inducible IEC-specific disruption of Mcl1 (i-Mcl1IEC mice); these mice and mice with full-length Mcl1
(controls) were raised under normal or germ-free conditions. Some mice were given antibiotics in their
drinking water or the PORCUPINE WNT inhibitor WNT974. Mice were analyzed by endoscopy and
for intestinal epithelial barrier permeability. Intestinal tissues were analyzed by histology, in situ hy-
bridization, proliferation assays, and immunoblots. Levels of calprotectin, a marker of intestinal inflam-
mation, were measured in intestinal tissues and feces. RESULTS Mcl1IEC mice spontaneously developed
apoptotic enterocolopathy, characterized by increased IEC apoptosis, hyperproliferative crypts, epithelial
barrier dysfunction, and chronic inflammation. Loss of MCL1 retained intestinal crypts in a hyperprolif-
erated state and prevented the differentiation of intestinal stem cells. Proliferation of intestinal stem cells
in MCL1-deficient mice required WNT signaling and was associated with DNA damage accumulation. By
1 year of age, Mcl1IEC mice developed intestinal tumors with morphologic and genetic features of human
adenomas and carcinomas. Germ-free housing of Mcl1IEC mice reduced markers of microbiota-induced
intestinal inflammation but not tumor development. CONCLUSION The anti-apoptotic protein MCL1,
a member of the BCL2 family, is required for maintenance of intestinal homeostasis and prevention of
carcinogenesis in mice. Loss of MCL1 results in development of intestinal carcinomas, even under germ-
free conditions, and therefore does not involve microbe-induced chronic inflammation. Mcl1IEC mice
might be used to study apoptotic enterocolopathy and inflammatory bowel diseases.
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Background & Aims 
Intestinal epithelial homeostasis depends on a tightly regulated balance between intestinal 
epithelial cell (IEC) death and proliferation. Disruption of factors that promote IEC death 
result in intestinal inflammation, whereas loss of anti-apoptotic proteins, such as BCL2 or its 
family member BCL2L1, has no effect on intestinal homeostasis in mice. We investigated the 
functions of the anti-apoptotic protein MCL1, another member of the BCL2 family, in 
intestinal homeostasis in mice. 
Methods 
We generated mice with IEC-specific disruption of Mcl1 (Mcl1∆IEC mice) or tamoxifen-
inducible IEC-specific disruption of Mcl1 (i-Mcl1∆IEC mice); these mice and mice with full-
length Mcl1 (controls) were raised under normal or germ-free conditions. Some mice were 
given antibiotics in their drinking water or the PORCUPINE WNT inhibitor WNT974. Mice 
were analyzed by endoscopy and for intestinal epithelial barrier permeability. Intestinal 
tissues were analyzed by histology, in situ hybridization, proliferation assays, and 
immunoblots. Levels of calprotectin, a marker of intestinal inflammation, were measured in 
intestinal tissues and feces.  
Results 
Mcl1∆IEC mice spontaneously developed apoptotic enterocolopathy, characterized by 
increased IEC apoptosis, hyperproliferative crypts, epithelial barrier dysfunction, and chronic 
inflammation. Loss of MCL1 retained intestinal crypts in a hyperproliferated state and 
prevented the differentiation of intestinal stem cells. Proliferation of intestinal stem cells in 
MCL1-deficient mice required WNT signaling and was associated with DNA damage 
accumulation. By 1 year of age, Mcl1∆IEC mice developed intestinal tumors with morphologic 
and genetic features of human adenomas and carcinomas. Germ-free housing of Mcl1∆IEC 
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The anti-apoptotic protein MCL1, a member of the BCL2 family, is required for maintenance 
of intestinal homeostasis and prevention of carcinogenesis in mice. Loss of MCL1 results in 
development of intestinal carcinomas, even under germ-free conditions, and therefore does 
not involve microbe-induced chronic inflammation. Mcl1∆IEC mice might be used to study 
apoptotic enterocolopathy and inflammatory bowel diseases. 
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Intestinal homeostasis is dependent on a tightly regulated interaction between the epithelium, 
the immune system and luminal commensal bacteria. The intestinal epithelium compartment 
is comprised of different cell types including proliferative stem cells as well as highly 
specialized absorptive (enterocytes) and secretory cells (goblet, Paneth and neuroendocrine 
cells)1, 2. These intestinal epithelial cells (IEC) provide a physical barrier between the 
intestinal mucosa and potentially pathogenic microorganisms. IEC display a high cell 
turnover, necessitating a strictly regulated balance of proliferation and cell death to 
guarantee intestinal epithelial homeostasis3. However, excessive IEC death is a well-known 
clinical hallmark of apoptotic enterocolopathy and inflammatory bowel disease (IBD)3-5. 
In recent years, there has been a great scientific interest in determining the roles played by 
cell death regulating molecules in maintaining tissue homeostasis and preventing 
tumorigenesis. Transgenic mice, generated with intestinal specific knockouts of particular 
IEC circuits of regulated cell death (RCD), FADD, Caspase 8 or RIPK1, display excessive 
IEC turnover, epithelial defects and IBD-like inflammation6-11. In contrast, mice harboring 
intestinal specific deletions of other RCD-molecules, BCL2 or BCL2L1, display surprisingly 
little pathology under steady state conditions. Although capable of modulating intestinal 
carcinogenesis in tumor models, both are dispensable for maintaining intestinal 
homeostasis12, 13. Interestingly, another pro-survival BCL2 family member, MCL1, is essential 
for maintaining homeostasis in several tissues with regenerative capacity14-16. The 
indispensable role for MCL1 in maintaining liver homeostasis15, 16 prompted us to study its 







Materials and Methods 
Mice: Housing and experimental procedures of all animals were performed in accordance 
with the Cantonal Veterinary Office (Zurich, Switzerland) under the license numbers 
ZH217/12 and ZH166/15 or the UK Home Office regulations (licence 70/8646) according to 
ARRIVE guidelines. Animals were maintained under SPF conditions at the University of 
Zurich or at the CRUK Beatson Institute, Glasgow. Germ-free housing of mice was 
performed within the Clean Mouse Facility of the University of Bern17. A detailed description 
of the generation of each mouse line is provided in the Supplemental material. 
 
Antibiotic (ABX) treatment: Ciprofloxacin (200mg/L) (Fluka), Ampicillin Sodium (1g/L) 
(Sigma), Metronidazole (1g/L) (Fluka) and Vancomycin HCl (500mg/L) (Fluka) were added to 
the drinking water of co-housed, 1-month-old wild type control and Mcl1∆IEC mice for 4 
weeks18. 
 
ILC depletion:  2-month-old Mcl1∆IECRag1-/- mice were treated with α-Thy1.2 depleting 
antibody (200µg) (BioxCell – clone:30H12) or appropriate isotype control via IP injection, 3 
times per week for 4 weeks.  
 
WNT signalling inhibition:  i-Mcl1∆IEC mice or wild type controls received 5mg/kg of WNT974 
(provided via an MTA with Novartis) orally, twice per day, in a 0.5% methylcellulose, 0.5% 
tween 80 vehicle.  
 
BrdU proliferation analysis:  BrdU (Amersham Biosciences) was administered via IP 
injection 2 hours before sacrificing. The number of BrdU positive crypts was determined by 
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calculating the average number of BrdU positive crypt cells per half crypt from 50 individual 
crypts. 
 
Intestinal epithelial barrier permeability: Intestinal epithelial barrier permeability was 
measured using FITC-labelled dextran (FD-4) as previously described19. Serum expression 
of FD-4 was determined using a BioTek Microplate Reader (BioTek). 
 
Endoscopy: Direct visualization of colonic mucosal damage of WT and Mcl1∆IEC mice was 
performed via high-resolution endoscopy using a “Coloview system” (Karl Storz, Tuttlingen, 
Germany). Mice were provided with food and water as normal until the endoscopy was 
performed. Isoflurane inhalation (2-2.5%) in oxygen was used to anaesthetize the mice for 
the duration of the procedure. 
 
Calprotectin analysis: Calprotectin (S100A8 and S100A9) levels were determined from 
homogenates of colon tissue (Real Time PCR) or feces (ELISA). Calprotectin primer 
sequences: S100A8 - For AAATCACCATGCCCTCTACAAG and Rev 
CCCACTTTTATCACCATCGCAA, S100A9 – For ATACTCTAGGAAGGAAGGACACC and 
Rev TCCATGATGTCATTTATGAGGGC. Reference gene (Gapdh) - For 
CCACCCCAGCAAGGAGACT and Rev GAAATTGTGAGGGAGATGCT. Protein levels of 
Calprotectin (S100A8 and S100A9) were determined by ELISA (Immune Diagnostik, 
#K6936). 
 
Histology: Formalin fixed tissue was embedded in paraffin. Paraffin sections were re-
hydrated and heat-induced antigen retrieval was performed in either Tris/EDTA/BORAT or 
citrate buffer. Incubation in Ventana buffer and staining was performed on a BenchmarkUltra 
immunohistochemistry robot (Ventana Instruments) using Chromo Map or Optiview Dab 
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Detection Kits (Ventana) or on a Bond MAX (Leica). All primary antibodies used for 
immunohistochemistry are listed in Table S2. A detailed description of the criteria used for 
the histological scoring is available in the Supplemental material (Table S5).  
 
Tumor classification: H&E stained slides of intestinal lesions, blinded for genotype and 
housing conditions, were independently evaluated by two pathologists. Tumor classification 
was based on established nomenclature and criteria for the histologic assessment of 
intestinal tumors in mice20. According to the criteria for the classification of human intestinal 
tumors, a small bowel neoplasm with infiltrative growth in the mucosa was classified as a 
carcinoma21. In cases where mice developed multiple tumors, classification was performed 
according to the highest lesion. 
 
In situ hybridization: ISH was performed on FFPE tissues according to the manufacturer`s 
protocol using four commercially available probes. A detailed description of all probes used 
in this study can be found in the Supplemental material.  
 
Ex vivo cytokine expression analysis: Ex vivo cytokine analysis was performed using 
supernatant recovered from colon cultures as previously described22. Supernatant was 
collected after 48 hours and cytokine expression was determined using Multiplex analysis 
kits (Bio-Rad Laboratories) and read using Bio-Plex® MAGPIXTM Multiplex Reader powered 
by Luminex XMAP Technology (Bio-Rad Laboratories). 
 
Sequencing: Genomic DNA was isolated from FFPE tissue blocks using Macherey & 
Nagel’s NucleoSpin FFPE Kit and analysed by Sanger Sequencing or Whole Exome 
Sequencing. A detailed description of the sequencing protocols used for are available in the 
Supplemental material.  
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RNASeq analysis was performed on RNA extracted from whole small intestine tissue of i-
Mcl1∆IEC mice (4 days post deletion) or i-Apc∆IEC and i-Apc∆IEC Mcl1∆IEC mice (3 days post 
deletion). A detailed description of the RNASeq protocol is provided in the Supplemental 
material. GSEA analysis was performed using the GSEA v2.0 software (Broad Institute). The 
comparison gene sets were obtained from published sources; genes upregulated following 
APC loss23 & WNT target genes commonly upregulated in human colorectal cancer24. 
 
Single molecule FISH (smFISH): smFISH was performed as previously described25. A 
comprehensive description of the protocol, including quantification and probes used (Tables 
S3-S5), is provided in the Supplemental material.  
 
Statistical analysis: Statistical analyses were conducted as indicated within each figure 
legend. For all analysis, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. Statistical analyses were 





MCL1 is a key regulator of intestinal homeostasis 
To unravel the physiological role of MCL1 within the intestinal tract, we generated mice with 
an IEC-specific deletion of Mcl1 (Mcl1∆IEC mice) (Figure S1A). Compared with littermate 
controls, Mcl1∆IEC mice developed extensive diarrhea, reduced weight gain and significantly 
increased mortality (Figure 1A). Colonoscopies performed on 4-month-old Mcl1∆IEC mice 
revealed extensive thickening and whitening of the colonic wall and distinct polyp formation 
(Figure 1A). Furthermore, 2-month-old Mcl1∆IEC mice displayed an impaired epithelial barrier 
function, as demonstrated by increased permeability of orally administered FITC-labeled 
dextran (Figure 1B). Elevated levels of S1008/S1009 (calprotectin), a biomarker of intestinal 
inflammation, were also detected in stool samples and tissue homogenates from Mcl1∆IEC 
mice (Figure 1C).  
Interestingly, not all IEC within Mcl1∆IEC mice underwent Mcl1 recombination and 
subsequently Mcl1∆IEC mice displayed areas that retained Mcl1 expression alongside areas of 
Mcl1 deficiency. Consequently, areas of severe mucosal damage appeared alongside 
histologically normal regions of both the small intestine and colon. Interestingly, IEC in 
histologically normal mucosal regions retained Mcl1 mRNA expression while IEC from 
damaged mucosal regions lacked Mcl1 (Figure 1D). Furthermore, S1008/S1009 levels were 
inversely correlated with Mcl1 expression, indicating the severity of intestinal damage was 
closely correlated with Mcl1 deficiency (Figure S1B). Histopathological analysis of 2-month-
old Mcl1∆IEC mice showed architectural disarray with crypt hyperplasia, villous atrophy (small 
intestine), increased IEC apoptosis (rather than necroptosis) (cleaved caspase 3) and 
hyperproliferative crypts (Ki-67) throughout both the colon and small intestine (Figures 1E-F, 
S1C-F). Notably, deleting a single copy of the Mcl1 gene was not sufficient to induce the 





MCL1 deficiency results in microbiota-induced chron ic inflammation 
In addition to the impaired epithelial barrier function described above, we also observed a 
marked decrease in the protective mucus layer at the intestinal mucosal barrier as well as 
extensive bacterial translocation from the lumen into the mucosa in Mcl1∆IEC mice (Figure 
S3A). Taken together, we concluded that MCL1 deficiency resulted in major epithelial cell 
dysfunction and chronic intestinal inflammation. Indeed, large lymphoid follicles, comprising 
mainly B and T cells, as well as an increased number of infiltrating immune cells were 
detected within the mucosa of Mcl1∆IEC mice (Figure S4A). In addition, pro-inflammatory 
cytokines TNF-α, IL-22, IL-23A, IL-17A, IL-17F and IL-1β were significantly in Mcl1∆IEC mice 
(Figure 1G and S4B). To determine the contribution of adaptive immune cells to mucosal 
inflammation and subsequent pathology following Mcl1 deletion, Mcl1∆IEC mice were inter-
crossed with Rag1-/- mice (Mcl1∆IECRag1-/- mice). Unexpectedly, Mcl1∆IECRag1-/- mice 
exhibited significantly reduced weight gain and shorter survival compared to both wild type 
and Mcl1∆IEC mice (Figure 2A). In addition, Mcl1∆IECRag1-/- mice also retained increased IEC 
apoptosis, hyperproliferative crypts, extensive mucosal damage (Figures 2B-C, S5A-B) and 
elevated levels of pro-inflammatory cytokines despite lacking conventional T cells (Figures 
2D, S5C-D). Given the observed cytokine profile, we postulated that innate lymphoid cells 
(ILC)26 were driving chronic intestinal inflammation, at least in the absence of conventional T 
cells. To test this hypothesis, ILC were depleted in 2-month-old Mcl1∆IECRag1-/- mice 
following a 4-week treatment with α-Thy1.2 antibody. Thy1 (CD90) positive cell depletion 
(Figure S6A) improved MCL1 deficiency-associated damage and resulted in the significant 
reduction of pro-inflammatory cytokines IL-22 and IL-17F (Figure 2E-F, S6B). However, 
increased IEC apoptosis and hyperproliferation persisted after ILC depletion (Figure 2E). 
Thus, by showing that MCL1 is indispensable for intestinal homeostasis, we identified a 




Increased IEC apoptosis and hyperproliferation are a direct consequence of Mcl1 
deletion 
In order to delineate whether the increased IEC apoptosis and hyperproliferation observed in 
Mcl1∆IEC mice were caused by the aforementioned chronic inflammation, or a direct result of 
MCL1 deficiency, Mcl1∆IEC mice were either placed under antibiotic treatment (ABX)18, or re-
derived under germ-free conditions17 (Figure S7A-B). Following 4 weeks of ABX treatment, 2-
month-old Mcl1∆IEC mice showed attenuated damage and significantly reduced intestinal 
inflammation compared to untreated Mcl1∆IEC mice (Figures S8A). However, ABX-treated 
Mcl1∆IEC mice retained increased IEC apoptosis and hyperproliferative crypts (Figure S8A). 
Similarly, germ-free Mcl1∆IEC mice displayed increased mucosal healing and a distinct lack of 
the immune cell infiltration observed in SPF Mcl1∆IEC mice (Figures 3A-B, S8B-C and S9A-B). 
Mcl1 deletion under germ-free conditions did not result in increased pro-inflammatory 
cytokine production when compared with littermate controls despite evidence suggesting an 
impaired intestinal epithelial barrier (Figure 3C, S8D, S10A). However, ameliorating chronic 
intestinal inflammation did not prevent the increased IEC apoptosis or hyperproliferation 
associated with Mcl1 deletion (Figures 3A, S8B). Collectively these data show that whereas 
MCL1 deficiency related chronic inflammation was due to an uncontrolled immune response 
against disseminating microbiota, increased IEC apoptosis and hyperproliferation directly 
result from MCL1 deficiency. 
 
MCL1 is essential for intestinal stem cell homeosta sis and differentiation 
Morphological analysis of the crypt compartments (Figure 1E) suggested that cellular 
compartmentalization was significantly dysregulated throughout the small intestine and colon 
of Mcl1∆IEC mice. Indeed, immunohistochemical analysis revealed that, following Mcl1 
deletion, intestinal stem cells (ISC) were not capable of differentiating towards secretory 
lineages. Mcl1∆IEC mice showed a complete loss of both goblet (AB/PAS positive) and Paneth 
cells (Lysozyme positive) in damaged (MCL1 deficient) areas (Figure 4A-C and S11A). Of 
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note, in unaffected areas (MCL1 positive), ISC retained their differentiation capabilities, and 
produced both goblet and Paneth cells at a comparable rate to control mice (Figures 4B-C). 
Impaired ISC differentiation was also observed in affected compartments of germ-free 
Mcl1∆IEC mice, delineating the necessity for MCL1 in retaining intestinal homeostasis and ISC 
differentiation from chronic inflammation. 
Interestingly, MCL1 deficient undifferentiated and hyperproliferative cells also retained the 
ISC markers OLFM4, SOX9 and Lgr5 (restricted to the base of the crypts under steady state 
conditions) throughout mid to apical parts of crypts (Figure 4A and S11B). To elucidate the 
molecular basis of this impaired ISC differentiation, we focused on the expression of Atoh1, 
an essential transcription factor for the differentiation of ISC towards the secretory cell 
lineages27. Interestingly, we observed a significant reduction in Atoh1 expression in Mcl1-
deficient ISC compared to Mcl1-positive ISC within the same mouse using single molecule 
fluorescent in situ hybridization (smFISH) (Figure 4D-E and S12A-B). These results suggest 
that, in the absence of MCL1, the axis of ISC proliferation and differentiation is constrained 
and polarized towards a highly proliferative ISC dominant environment.   
Given the well-established connection between hyperproliferation, replicative stress and DNA 
damage16, 28, we next sought to look for evidence of DNA damage accumulation. 
Immunohistochemical staining for the DNA damage response marker γH2AX, revealed 
strong positivity within the crypts of Mcl1∆IEC mice. γH2AX positivity was consistently found in 
Mcl1-deficient IEC but not in Mcl1-expressing IEC or IEC of littermate controls (Figure S13A-
B). Furthermore, γH2AX positivity was also observed under germ-free conditions, 
independent of chronic inflammation. Altogether, MCL1 deficiency restricts ISC to an 
undifferentiated and hyperproliferative state that makes the ISC susceptible to the 






MCL1-deficiency associated ISC hyperproliferation i s dependent on WNT signaling 
To further investigate the direct consequences of Mcl1 deletion and how it translates to IEC 
hyperproliferation and loss of differentiation, we generated a tamoxifen-inducible IEC-specific 
Mcl1 knockout mouse (i-Mcl1∆IEC mice). Importantly the phenotype of i-Mcl1∆IEC mice closely 
recapitulated the phenotype of Mcl1∆IEC mice. The epithelium of i-Mcl1∆IEC mice displayed 
architectural disarray with crypt hyperplasia, villous atrophy (small intestine), increased IEC 
apoptosis and IEC hyperproliferation throughout the small intestine and the colon (Figure 5A, 
S14A). i-Mcl1∆IEC mice also displayed impaired epithelial barrier function and a markedly 
increased immune infiltration (3-4 days post induction) (Figures S14A-C). ISC differentiation 
to secretory lineages was also significantly reduced in i-Mcl1∆IEC mice illustrated by a marked 
reduction in both goblet and Paneth cells following Mcl1 deletion (Figure 5B). In addition, i-
Mcl1∆IEC mice also displayed strong γH2AX positivity, detectable throughout the small 
intestine and colon following Mcl1 deletion (Figure 5B). In addition, gene set enrichment 
analysis (GSEA from RNAseq data), indicated a strong enrichment for genes commonly up-
regulated in response to the detection of DNA damage and post-replication DNA repair in i-
Mcl1∆IEC mice compared to littermate controls (Figures 5C and S15A). These data further 
corroborated that the γH2AX positivity associated with Mcl1 deletion was indeed indicative of 
DNA damage.  
i-Mcl1∆IEC mice displayed complete Mcl1 recombination throughout the entire intestine 
(compared to the “patchy” recombination described in Mcl1∆IEC mice) and so represented a 
valuable tool by which to more accurately investigate the molecular consequences to Mcl1 
deletion (Figure S16A). Interestingly, i-Mcl1∆IEC mice displayed a strong activation of wound 
healing programs and increased expression of WNT target genes as determined by RNASeq 
analysis (Tables S13 and S14). Moreover, following Mcl1 deletion, GSEA also indicated an 
enrichment for genes commonly up-regulated in human colorectal cancer (CRC) as well as 
mice with an IEC-specific deletion of adenomatous polyposis coli (Apc), a prototypical model 
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for intestinal tumorigenesis29 (Figures 5D and S14D). To test whether MCL1 deficiency-
associated hyperproliferation observed within the ISC compartment was dependent on WNT 
signaling, we co-deleted a single copy of the canonical WNT pathway mediator Ctnnb1 (β-
catenin) in conjunction with Mcl1 (i-Ctnnb1∆IEC/wtMcl1∆IEC mice). Deleting a single copy of 
Ctnnb1 was sufficient to partially rescue the hyperproliferative phenotype associated with 
Mcl1 deletion (Figures 5E and S17A). Subsequently, i-Mcl1∆IEC mice were treated with the 
WNT signaling/porcupine inhibitor WNT974. Strikingly, WNT974 treatment completely 
ameliorated hyperproliferation within the crypts of both the small intestine and colon of i-
Mcl1∆IEC mice (Figures 5F, S17B and S18A-B). Collectively, these data suggest that the 
impaired intestinal homeostasis following Mcl1 deletion inflicts a WNT-induced 
hyperproliferative state on undifferentiated IEC.  
To determine whether increased WNT signaling observed following Mcl1 deletion was a 
direct or indirect consequence of Mcl1 deletion, we next used smFISH to visualize Wnt2b 
molecules within the stroma of Mcl1∆IEC mice. Firstly, Wnt2b expression levels were markedly 
increased within the stroma of damaged areas (Mcl1-deficient) compared to unaffected areas 
(Mcl1-expressing) (Figure 5G and S19A-B). Secondly, IEC did not express Wnt2b 
irrespective of Mcl1 expression. Wnt2b expression was completely restricted to the pool of 
Mcl1-positive cells within the stroma surrounding the intestinal crypts (Figure 5G and S19A-
B).  
In order to delineate a potential effect of MCL1 deficiency in driving IEC proliferation from the 
effect of increased WNT signaling, we next generated a tamoxifen-inducible knockout mouse 
which facilitated the simultaneously delete both Mcl1 and the essential negative regulator of 
WNT signaling Apc (i-Apc∆IECMcl1∆IEC mice). As previously described, Apc deletion (i-Apc∆IEC 
mice) resulted in increased crypt proliferation and subsequent hyperplasia as a result of 
constitutive WNT signaling (Figure 6A). Remarkably, co-deletion of Apc and Mcl1 resulted in 
a further significant increase in crypt proliferation throughout the small intestine and colon 
(Figure 6A). RNAseq analysis from these mice also showed significantly higher expression of 
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essential proliferation associated genes Pcna, Cdk1, Cdk4 and E2f1, as well as marked 
increases in Ccnd1 and cMyc, which was not attributable to activated WNT signaling (Figure 
6B-D and S20A-C). Similar to Mcl1∆IEC mice, IEC proliferation was intrinsically linked to 
increased apoptosis irrespective of the increased WNT signaling (Figure S20D). These 
results demonstrate that even in the presence of constitutive WNT signaling, the loss of Mcl1 
directly increases IEC proliferation beyond the levels obtained by WNT signaling alone. 
Despite the clear growth advantage observed in MCL1 deficient ISC in vivo, it was 
surprisingly not possible to establish a viable line of Mcl1 deficient organoids from Mcl1∆IEC 
mice. Interestingly, while it was possible to establish a low yield of organoids from the small 
intestine of i-Mcl1∆IEC mice, the organoids which formed had escaped recombination and 
retained Mcl1 expression (Figure 6E). Remarkably, organoids derived from the small 
intestine of i-Apc∆IECMcl1∆IEC mice were viable and retained Mcl1 deficiency through at least 5 
passages (Figure 6F-G and S21A). These observations suggest that the activation of WNT 
signaling and subsequent WNT saturated environment is essential for the survival of MCL1 
deficient ISC. Collectively, these results not only demonstrate that MCL1 deficiency is 
intricately linked to an activated WNT signaling pathway, but that a clear proliferation-
enhancing effect exists that is directly attributable to MCL1 deficiency. 
 
Mcl1 deficiency results in carcinoma development 
Given the increased proliferation and undifferentiated state of MCL1 deficient ISC, together 
with the intestinal polyps observed in 4-month-old Mcl1∆IEC mice (Figure 1A), we next aimed 
to monitor the long-term sequelae of MCL1 deficiency. Strikingly, we found that life-long 
MCL1 deficiency resulted in intestinal tumorigenesis (Figure 7A). By one year, >80% of 
Mcl1∆IEC mice displayed intestinal neoplasms within the small intestine and/or colon. 
Remarkably, intestinal tumors developed with similar incidence under both SPF and germ-
free conditions, therefore independently of microbe-induced intestinal inflammation (Figure 
7B). Lesions comprised a spectrum ranging from hyperplastic changes over low and high 
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grade adenomas to invasive carcinomas20, thus mirroring Vogelstein`s adenoma-carcinoma-
sequence of human intestinal carcinogenesis30 (Figure 7C, S22A). Carcinoma found in 
Mcl1∆IEC mice extended deep into the muscularis propria (black box) and infiltrated intestinal 
vasculature (black circle) (Figure 7C). Of note, tumors were consistently MCL1 deficient and 
multiclonal in origin as shown by lineage tracing with the multicolor Cre-reporter R26R-
Confetti31 (Figures 7D and S22B). MCL1 deficient tumors also displayed inter- and 
intratumoral heterogeneity with respect to differentiation markers such as CD44, CDX2 and 
synaptophysin (Figure S22C). Furthermore, tumors displayed regional Axin2 positivity and β-
catenin nuclear localization indicating responsiveness to active WNT signaling and/or Ctnnb1 
mutations (Figures 7E-F and S22D).  
While progressing through the adenoma-carcinoma-sequence, tumors increasingly displayed 
genomic alterations in terms of non-recurrent chromosomal aberrations as determined by 
array comparative genomic hybridization (aCGH), as well as single nucleotide variants (SNV) 
as determined by whole exome and Sanger sequencing (Figure 7G). Remarkably, Synteny 
analysis revealed a statistically significant overlap of chromosomal gains and losses with 
those found in human colorectal carcinomas (CRC) (78.3% of gains and 69.8% of losses; 
Figure 7H)32. Strikingly, SNV comprised functionally relevant mutations in genes of the WNT 
pathway frequently also mutated in human CRC such as CTNNB1, APC, FBXW7 and 
ARID130, 32, 33 (Figure S23A). 
Collectively, these findings demonstrate that carcinogenesis in Mcl1∆IEC mice morphologically 
and genetically closely recapitulates human intestinal carcinogenesis30, 33. Furthermore, since 
tumors develop under germ-free conditions, MCL1 deficiency-related tumorigenesis is 






In this study, we have identified an essential role for MCL1 in preserving intestinal 
homeostasis and preventing carcinoma formation, previously undescribed among BCL2 anti-
apoptotic family members. These findings, in particular the microbiota-independency of 
MCL1 deficiency-associated tumorigenesis, clearly demonstrate an essential role for MCL1 
in preserving intestinal homeostasis. These results may have important implications for 
understanding the pathogenesis of apoptotic enterocolopathy, IBD and CRC development.  
Disturbances in epithelial barrier integrity with dysfunctional IEC–intrinsic molecular circuits 
that control tissue homeostasis, renewal, and the repair of IEC are cardinal features of both 
apoptotic enterocolopathy and IBD. Remarkably, intestinal pathology due to IEC-specific 
MCL1 deficiency shared hallmark features with IBD, including barrier dysfunction, chronic 
inflammation, increased IEC apoptosis, hyperproliferation and impaired ISC differentiation1, 3, 
5. Thus, Mcl1∆IEC mice may represent a pertinent preclinical model of both apoptotic 
enterocolopathy and IBD, while also opening up the possibility that (even a temporally 
restricted) dysregulation of MCL1 may contribute to the development of these, and similar, 
conditions. 
Given the well-established increased risk for IBD patients to develop intestinal carcinomas, 
which increases parallel to the duration and severity of their disease35, it was interesting to 
discover that Mcl1∆IEC mice also spontaneously developed intestinal carcinomas. Remarkably 
however, while chronic inflammation has been established as a major driver of intestinal 
carcinoma35, MCL1 deficiency-related carcinoma formation was independent of microbe-
induced chronic inflammation.  
Given the multifaceted and crucial roles of MCL136, various mechanisms are conceivable to 
explain MCL1 deficiency-related tumorigenesis. Of note, tumor lesions observed in Mcl1∆IEC 
mice exhibited the full spectrum of human CRC development described by Vogelstein et al.30, 
ranging from dysplastic crypts and low grade adenoma to high grade adenoma and 
carcinoma. Interestingly, tumors that developed as a result of MCL1 deficiency not only bear 
a striking similarity to human CRC, but revealed significant correlations with the subgroup of 
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CRC characterized by active WNT signaling. These results indicate a potentially direct and 
immediate function for MCL1 in regulating IEC proliferation and suppressing tumor formation, 
the functional consequence of which becomes obvious in the presence of constitutive WNT 
signaling. This scenario not only explains the mutational spectrum observed in MCL1 
deficient tumors, with clear enrichment of genes associated with WNT signaling32, but also 
explains the differential viability observed in ex vivo organoid cultures derived from the 
intestines of i-Mcl1∆IEC mice compared to those derived from i-Apc∆IECMcl1∆IEC mice. Ex vivo 
culture of Mcl1 deficient organoids was only possible with the added deletion of Apc 
indicating that the survival of Mcl1 deficient ISC is dependent on the cell-intrinsic activation of 
WNT signaling. At the same time, we clearly show that in the presence of constitutive WNT 
signaling, Mcl1 has a direct role in regulating ISC proliferation.  
MCL1 deficient ISC, which retain OLFM4, Lgr5 and SOX9 positivity, did not differentiate into 
the secondary secretory lineages as illustrated by a complete loss of both Paneth and goblet 
cells. This loss of differentiation is restricted to Mcl1 deficient (phenotypic) regions of Mcl1∆IEC 
mice. Interestingly, Mcl1 deficient ISC showed a significant reduction of the transcription 
factor Atoh1, essential for the differentiation to secondary secretory lineages27. However, ISC 
from Mcl1-expressing (non-phenotypic) areas retain high Atoh1 expression levels and 
differentiate to Paneth and goblet cells at a similar rate to wild type ISC. The inability of 
MCL1 deficient ISC to differentiate to secretory cells was also observed under germ-free 
conditions, removing the potential influence of chronic inflammation. Whether or not this 
reduced Atoh1 expression is a direct result of MCL1 deficiency or is a secondary effect of a 
WNT-signaling saturated environment deserves further investigation. These data suggest 
that MCL1 is essential for maintaining the strictly controlled balance between ISC 
proliferation and differentiation and the polarization of ISC towards a hyperproliferative state 
in the absence of MCL1 may facilitate genetic alterations predisposing to tumorigenesis. 
Additionally, the strong positivity of γH2AX following Mcl1 deletion within Mcl1∆IEC and i-
Mcl1∆IEC mice may also be important in the context of tumor formation and further studies are 
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required to determine the significance of this observation. These γH2AX positive cells 
potentially represent IEC that had accumulated DNA damage but escaped apoptotic 
programming. DNA damage is a well-established hallmark of tumorigenesis28, and following 
Mcl1 deletion, may originate from the increased replicative stress. The potential role of MCL1 
in maintaining DNA replication integrity is very intriguing and our findings support recent 
publications describing increased replicative stress and higher susceptibility to DNA double 
strand breaks37, 38 and the strong synergistic effects of combining MCL1 and PARP-1 
inhibitors to treat certain tumors37, 39. Collectively, these recent findings strongly suggest a 
non-redundant role for MCL1 in maintaining DNA replication integrity, the absence of which 
may result in DNA damage and potentially tumor initiation, as observed in Mcl1∆IEC mice.  
Conceptually, these findings show that, depending on the context, MCL1 dysregulation can 
promote tumorigenesis by different means. On one hand, although very rare in human 
cancers40, it is conceivable that early steps of carcinogenesis may be induced by severely 
impaired intestinal homeostasis resulting from, even transient, gene alterations and loss of 
MCL1 function. On the other hand, amplifications of chromosome 1 resulting in over-
expression of MCL136, 41, a recurrent finding in a variety of cancers including CRC, is well 
known to confer a survival advantage within tumors42. Thus, pharmacologic inhibition of 
MCL1 recently has emerged as an attractive target to increase the susceptibility of different 
tumors to conventional anti-tumor therapies39, 43, 44. Although recently published MCL1 
inhibitors have been shown to be tolerable and functional in a number of different cancer 
models45, 46, intestinal pathology due to pharmacological inhibition of MCL1 has not yet been 
extensively addressed. A complete lack of adverse effects within the intestinal epithelium 
would be surprising given the MCL1 dependency of IEC shown in this study.  
In summary, we not only demonstrate the crucial role for MCL1 in maintaining intestinal 
homeostasis, but also uncover an unexpected tumor suppressor capacity for MCL1 within 
the intestinal tract. These findings may contribute to unravelling the early stages of intestinal 
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cancer development, and may have important implications for current strategies aimed at 
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Figure 1: MCL1 is essential for maintaining intesti nal homeostasis. (A) Mcl1∆IEC mice 
show reduced weight gain (n=50) and survival (n=126) compared to littermate controls (n=34 
and n=61 respectively). Representative colonoscopy images from 4-month-old mice. (B) 2-
month-old Mcl1∆IEC mice display increased FITC-dextran (n=13) compared with littermate 
controls (n=8) 4 hours after oral administration. (C) Calprotectin (S100A8/S100A9) levels of 
2-month-old Mcl1∆IEC mice and age-matched controls by ELISA (n=6 Mcl1∆IEC mice, n=9 wild 
type) or real time PCR (n=8 Mcl1∆IEC mice, n=5 wild type).  (D) Representative images 
illustrating Mcl1 expression in the colon (red stain) as demonstrated using ISH (scale bars: 
100µm). (E) Representative images from the colon of 2-month-old Mcl1∆IEC mice compared 
with age-matched controls (scale bars: 100µm , 25µm-inserts). (F) Blinded histological 
scores comparing the colon of 2-month-old Mcl1∆IEC mice with littermate controls (n=5). (G) 
Colon cultures established from 2-month-old mice and analysed using multiplex analysis 
(minimum n=10 per group). Data presented as either bar charts or scatter plot graph show 
mean values ± s.e.m. Statistical analyses were conducted by one-way ANOVA with 
Bonferroni correction (A (body weight), G), log rank (Mantel-Cox test) (A, survival), student’s 
















Figure 2: MCL1 deficiency-associated chronic inflam mation is mediated by ILC. (A) 
Genetic depletion of Rag1 within Mcl1∆IEC mice significantly reduced weight gain and survival 
(n=19). Blue asterisk: Mcl1∆IEC mice compared to littermate controls, red asterisk: 
Mcl1∆IECRag1-/- mice compared to littermate controls, purple asterisk: Mcl1∆IEC mice 
compared with Mcl1∆IECRag1-/- mice. (B) Representative images from the colon of 2-month-
old Rag1-/- control mice compared with Mcl1∆IECRag1-/- mice showing impaired intestinal 
architecture (H&E), increased IEC apoptosis (cl. casp. 3) and hyperproliferation (Ki-67) 
(scale bars: 100µm, 25µm-inserts). (C) Blinded histological scores comparing 2-month-old 
Mcl1∆IECRag1-/- mice with Rag1-/- mice (n=5). (D) Colon cultures established from 2-month-old 
mice and analysed using multiplex analysis (minimum n=8 per group). (E) Representative 
images from colons of 3-month-old Mcl1∆IECRag1-/- mice following 4 weeks of α-Thy1.2 
depleting antibody or corresponding isotype administration (scale bars: 100µm, 25µm-
inserts). (F) Colon cultures established from 3-month-old mice and analysed for TNF-α, IL-
22, IL-23A, IL-17A, IL-17F and IL-1β expression using multiplex analysis (minimum n=8 per 
group). Data presented as either bar charts or scatter plot graph show mean values ± s.e.m. 
Statistical analyses were conducted by one-way ANOVA with Bonferroni correction (A (body 
weight), D and F), log rank (Mantel-Cox test) (A, survival) or Mann-Whitney test (C) where * 















Figure 3: IEC apoptosis and hyperproliferation are a direct consequence of Mcl1 
deletion. (A) Representative images from the colon of 2-month-old germ-free Mcl1∆IEC mice 
compared with littermate controls illustrating increased IEC apoptosis (cl. casp. 3) and 
hyperproliferation (Ki-67) (scale bars: 100µm, 25µm-inserts). (B) Blinded histological scores 
comparing 2-month-old Mcl1∆IEC mice with littermate controls under germ-free conditions 
(n=5 per group). (C) Colon cultures established from 2-month-old germ-free mice and 
analysed using multiplex analysis (minimum n=15 per group). Data presented as either bar 
charts or scatter plot graphs represents mean values ± s.e.m. Statistical analyses were 
conducted by Mann-Whitney test (B) or by one-way ANOVA with Bonferroni correction (C) 
























Figure 4: MCL1 is essential for ISC differentiation . (A) Representative images from the 
small intestine of 2-month-old Mcl1∆IEC mice compared with age matched controls illustrating 
impaired goblet (AB/PAS) and Paneth cell (Lysozyme) differentiation, increased proliferation 
(Ki-67) and retention of stem cell markers (OLFM4 and SOX9) (scale bars: 100µm). (B) 
Quantification of total goblet (AB/PAS) and Paneth cells (Lysozyme) in the small intestine. 
(C) Quantification of total goblet (AB/PAS) cells in the colon. (D) Representative images from 
the small intestine of Mcl1∆IEC mice visualising Atoh1 expression in Mcl1-positive versus 
Mcl1-deficient IEC using smFISH. White dots represents single molecules of Atoh1 while red 
dots represent Mcl1. * indicates overexposed non-specific signal. Green boxes mark the 
areas shown in higher magnification below (scale bars: 25µm-upper, 10µm-lower). (E) 
Quantificaiton of Atoh1 smFISH signal (n=7 per group). Data presented as either bar charts 
or scatter plot graph show mean values ± s.e.m. Statistical analyses were conducted by 




















Figure 5: MCL1 protects the small intesitne from ac tivating WNT signalling and DNA 
damage. (A-B) Representative images from the small intestine of i-Mcl1∆IEC mice and age-
matched controls, (4 days post induction) (scale bars: 100µm, 25µm-insert). (C) Gene Set 
Enrichment Analysis (GSEA) carried out on RNA sequencing data from i-Mcl1∆IEC mouse 
compared with littermate controls. (D) GSEA analysis tested for WNT target genes 
commonly up-regulated in human CRC (upper) or in i-Apc∆IEC mouse models (lower). (E) 
BrdU staining from the small intestines of wild type, i-Ctnnb1∆IEC/wt, i-Mcl1∆IEC and i-
Ctnnb1∆IEC/wtMcl1∆IEC mice,4 days post induction (scale bars: 100µm). Quantification of BrdU 
staining (positive cells/half crypt) is shown below (n=3). (F) BrdU staining from the small 
intestines of vehicle treated wild type and i-Mcl1∆IEC mice compared with their WNT974 
treated counterparts, 3 days post induction (scale bars: 100µm). Quantification of BrdU 
staining (positive cells/half crypt) is shown below (n=3).  (G) Representative images from the 
small intestine of Mcl1∆IEC mice visualising Wnt2b expression in Mcl1-positive versus Mcl1-
deficient IEC using smFISH. White dots represents single molecules of Wnt2b while red dots 
represent Mcl1. * indicates overexposed non-specific signal. Green dashed lines represents 
the perimeter of intestinal crypts (scale bars: 25µm-lower magnification, 10µm-higher 
magnification). All data presented as scatter plot graph represents mean values ± s.e.m. 













Figure 6: MCL1 is an essential regulator of IEC pro liferation. (A) Representative images 
of small intestinal or colonic tissue from i-Apc∆IEC and i-Apc∆IECMcl1∆IEC mice (3 days post 
induction), and stained with H&E or for BrdU (scale bar: 50µm). Quantification of BrdU 
positive cells per half crypt from small intestine and colon (right panel). Normalised 
expression of Pcna (B), Cdk1 (C) and Cdk4 (D) in whole small intestine tissue from wild type 
controls and i-Mcl1∆IEC mice (4 post induction), or i-Apc∆IEC and i-Apc∆IECMcl1∆IEC mice (3 post 
induction) and analysed by RNAseq (n=3 per group). (E) Normalised expression of Mcl1 in 
whole small intestinal tissue at day 4 post induction (left) or small intestine derived organoids 
at passage ≥3 (right) from wild type or i-Mcl1∆IEC mice as analysed by RNAseq (n=3 per 
group). (F) Relative expression of Mcl1 in whole small intestinal tissue at day 3 post induction 
(left) or small intestine derived organoids at passage ≥5 (right) in i-Apc∆IEC or i-
Apc∆IECMcl1∆IEC mice as analysed by RNAseq (n=3 per group). (G) Representative images of 
small intestine derived organoids from i-Apc∆IEC or i-Apc∆IECMcl1∆IEC mice (100x). All data 
presented as scatter plot graph represents mean values ± s.e.m. Statistical analysis was 
















Figure 7: MCL1 protects from intestinal carcinoma d evelopment. (A) Representative 
images from colonoscopies (top), macroscopic imaging (bottom) and H&E characterisation of 
colon carcinoma found in 18-month-old Mcl1∆IEC mouse (scale bar: 500µm) (right). (B) 
Percentage and classification of tumor lesions observed in 12-month-old SPF Mcl1∆IEC mice 
(n=42) compared with germ-free Mcl1∆IEC mice (n=12). White sections: no tumor lesions or 
mucosal hyperplasia, light grey sections: low-grade adenomas (LGA), dark grey sections: 
high-grade adenomas (HGA), black sections: carcinoma (CA). In cases where more than a 
single lesion was present, individual mice were classified according to the highest tumor 
lesion. (C) IHC staining illustrating the invasive growth of carcinoma in Mcl1∆IEC mice. 
Carcinoma cells, α-SMA negative (black boxes) and cytokeratin positive (black arrow heads), 
actively invade the muscularis propria of a 18-month-old Mcl1∆IEC mouse (scale bar: 100µm 
scale bars). Black circle indicates vesicular invasion. (D) IHC analysis showing lack of MCL1 
expression in tumors that develop in Mcl1∆IEC mice (scale bar: 100µm-upper, 25µm-lower). 
(E) ISH for WNT target gene Axin2 (scale bar: 100µm-upper, 50µm-lower). (F) 
Representative IHC staining illustrating nuclear β-catenin localisation (white arrow heads) 
observed in a carcinoma from a 12-month-old Mcl1∆IEC mouse (scale bar: 100µm-upper, 
25µm-lower). Below, a heterozygous missense point mutation in a mutational hot spot region 
of exon 2 of Ctnnb1 (NM_000075.6:c.98C>T - p.Ser33Phe) (3/5 carcinomas sequenced). (G) 
aCGH analysis of tumors isolated from 12-month-old Mcl1∆IEC mice (from left to right: 8 
carcinoma samples, 2 adenoma samples and 2 unaffected samples from 18-month-old 
Mcl1∆IEC mice). (H) Synteny analysis comparing chromosomal aberrations in carcinomas 
from Mcl1∆IEC mice with human CRC (Murine chromosomes: M1-M19; Human chromosomes 
H1-H22). Statistical analyses for non-random distribution of matched copy number gains 









What you need to know: 
 
BACKGROUND AND CONTEXT: Intestinal epithelial homeostasis depends on a tightly 
regulated balance between intestinal epithelial cell (IEC) death and proliferation. Disruption 
of factors that regulate IEC death result in intestinal inflammation, whereas loss of anti-
apoptotic proteins, such as family members BCL2 and BCL2L1, have no effects on intestinal 
homeostasis in mice, 
 
NEW FINDINGS: The BCL2 family member MCL1 is required for maintenance of intestinal 
homeostasis and prevention of carcinogenesis in mice. Loss of MCL1 results in intestinal 
carcinogenesis—even under germ-free conditions, and therefore does not involve microbe-
induced chronic inflammation. 
 
LIMITATIONS: This study was performed in mice. Studies are needed to determine whether 
MCL1 function is disrupted in patients with inflammatory bowel diseases or cancer. 
 





We identified a protein, MCL1, that regulates proliferation of intestinal epithelial cells. Its 
loss might promote development of intestinal cancer. 
 
